

## NICE PUBLIC HEALTH GUIDANCE

### Needle and Syringe Programmes (update of PH18)

#### 2nd Meeting of the Public Health Advisory Committee

19<sup>th</sup> July 2013

Royal College of Paediatricians, 5-11 Theobolds Road, London

#### Final Minutes

<b>Attendees:</b>	<p><b>PHAC Members</b></p> <p><b>Core members</b> Susan Jebb (Chair), Mireia Jofre Bonet, Chris Packham, Amanda Sowden, Lucy Yardley, Joyce Rothschild</p> <p><b>Topic members</b> Vicky Fenwick, Adam Mackridge, Tony Margett, Fortune Ncube, , April Wareham, Paul Wells</p> <p><b>Co-optees</b> Joe Kean, Steroid Project Lead, Lifeline and Senior Trainer, Nine Zero Five</p> <p><b>NICE Team</b> Simon Ellis, Chris Carmona, Emma Doohan (minutes), Alastair Fischer, Suzi Peden, Louise Millward</p> <p><b>Review Teams</b> <i>Liverpool John Moores University:</i> Lisa Jones, Geoff Bates, Jim McVeigh <i>London School of Hygiene and Tropical Medicine:</i> Lucy Platt, Bethan McDonald, Neil Hunt</p> <p><b>Observers</b> Craig Moss (Addaction), Natalie Wood (Tiny Sparks project)</p>
<b>Apologies:</b>	<p><b>PHAC Members</b> Toby Prevost, Alison Lloyd</p> <p><b>NICE</b> James Jagroo</p>

<b>Author</b>	Emma Doohan, Project Manager
<b>File Ref</b>	Final minutes of PHAC 2 meeting on NSP update 19th July 2013
<b>Version</b>	Final (Chair approved)
<b>Audience</b>	<b>PHAC members, NICE team, members of the public</b>

Item		Action
<p><b>1. Welcome and objectives for the meeting</b></p>	<p>The Chair welcomed the Public Health Advisory Committee (PHAC), the NICE team, the review team and the observers to the 2nd meeting on Needle and Syringe Programmes (update).</p> <p>The Chair also welcomed the members of public to the meeting.</p> <p>The Chair outlined the general housekeeping for the venue.</p> <p>The chair outlined the aim of the meeting which was to agree the draft updated guidance on 'Needle and syringe programmes', to be released for public consultation on 24<sup>th</sup> September 2013.</p> <p>The objectives were outlined as follows:</p> <ul style="list-style-type: none"> <li>• To hear the final findings from the survey of commissioners and providers</li> <li>• To consider the health economic issues</li> <li>• To agree revisions to the current PH18 recommendations</li> <li>• To agree any new recommendations</li> <li>• To agree any new considerations</li> <li>• To agree the gaps and research recommendations.</li> </ul> <p>The Chair informed the PHAC that apologies had been received. These are noted above.</p>	
<p><b>2. Declarations of Interests</b></p>	<p>The Chair explained that verbal declarations of interest are a standing item on every agenda and are recorded in the minutes as a matter of public record.</p> <p>The Chair asked the PHAC to declare any changes to their conflicts of interest. Previous declarations of interest can be viewed in the minutes of meeting 1 on the NICE website here:  <a href="http://guidance.nice.org.uk/PHG/72">http://guidance.nice.org.uk/PHG/72</a></p> <p>The Chair and Associate Director of CPH had reviewed these interests previously and determined that the interests declared did not prevent the attendees from fully participating in the meeting.</p>	

	<p>The following additional DOIs were made:</p> <p><b><u>Personal non pecuniary</u></b></p> <p><b>Adam Mackridge</b> Has previously published papers in which he has concluded that community pharmacies could provide extended services to NSP users and stating that appropriate training is needed for community pharmacy staff providing NSP services.</p> <p>The Chair confirmed that this interest did not prevent Adam from fully participating in the meeting.</p>	
<p><b>3. Presentation by Geoff Bates, LJMU</b></p>	<p>Geoff Bates from the Liverpool John Moores University (LJMU) gave a presentation entitled '<b>Survey of NSP providers and commissioners re implementation of PH18: presentation of final report.</b>'</p> <p>The committee were given an opportunity to ask any questions about the report.</p>	
<p><b>4. Presentation by Alastair Fischer, NICE</b></p>	<p>Alastair Fischer from NICE gave a presentation about the health economics for the topic. He outlined why the health economic work from the previous guidance had not been extended to include PIEDs and young people.</p>	
<p><b>5. Questions and discussion</b></p>	<p>The committee were invited to ask any questions in regard to the presentation.</p> <p>A number of issues were raised and discussed.</p> <p>The chair asked the committee to consider the following:</p> <ul style="list-style-type: none"> <li>• Young people under 16 – are the committee satisfied that the cost effectiveness of NSP for young people will be the same or greater than for the general population of people who inject drugs?</li> <li>• Performance and image-enhancing drug users (PIEDs) – are the committee happy to make recommendations even though the cost effectiveness of NSP for this group is unknown?</li> </ul> <p><b>The following actions were agreed:</b></p> <ul style="list-style-type: none"> <li>• NICE team to extract further information on cost effectiveness from the modelling work that supported the original guidance.</li> <li>• A research recommendation about costs and benefits of extending services to PIEDS may</li> </ul>	<p><b>NICE team</b></p> <p><b>NICE team</b></p>

	be suggested in the final guidance.	
<b>6. Revisions to the original recommendations</b>	<p>The committee considered the revisions to the original recommendations from the NSP guidance published in 2009.</p> <p>The committee suggested amendments and additions to the recommendations which were noted by the team.</p>	
<b>7. Considering the new recommendations</b>	<p>The committee considered and made revisions to the two new recommendations that were drafted following the June meeting.</p> <p>The committee agreed on the changes to the young people's recommendation.</p> <p>The committee discussed whether to have a specific recommendation on PIEDs. It was agreed that a specific recommendation should be taken forward and the committee discussed the amendments to the recommendation that had been drafted following the June meeting.</p> <p>The committee suggested some further research recommendations.</p> <p>The committee suggested a new recommendation on monitoring.</p>	
<b>8. Revisions to the considerations</b>	<p>The committee were asked to look at the new considerations that were drafted following the June meeting.</p> <p>The NICE team noted the suggested revisions and additions.</p>	
<b>9. Revisions to gaps and research recommendations</b>	<p>The committee worked through the research recommendations that were drafted following the June meeting and made changes and additions.</p> <p><b>Action:</b> NICE team to highlight the research recommendations that are new and ones that have been carried forward from the last guidance.</p>	<b>NICE</b>
<b>10. Next steps</b>	<p>Simon Ellis outlined the next steps in guidance production as follows:</p> <ul style="list-style-type: none"> <li>• NICE team to complete the revisions and additions to the recommendations. These will then be edited.</li> <li>• The complete pre-consultation draft guidance will be circulated to committee members on 9<sup>th</sup> August for comment by 3<sup>rd</sup> September.</li> </ul>	

Final minutes of PHAC 2 meeting on NSP update 19th July 2013

	<ul style="list-style-type: none"><li>• The NICE team will meet with the Chair on 6<sup>th</sup> September to agree final revisions.</li><li>• Draft guidance will be released for consultation on 24<sup>th</sup> September.</li></ul>	
<b>11. AOB</b>	<ul style="list-style-type: none"><li>• The committee were reminded that expenses should be submitted within 3 months of the meeting.</li><li>• The next meeting of PHAC A is being held on Wednesday 4<sup>th</sup> September to discuss the guidance on Vitamin D. Needle and Syringe topic members will not need to attend this meeting.</li><li>• The next Needle and Syringe PHAC meeting is being held on Friday 22<sup>nd</sup> November.</li></ul>	
<b>12. Close</b>	The meeting closed at 4.15pm.	